Cel People often use over-the-counter (OTC) medicines to treat minor health problems and see these medicines as safe. Yet, like any other, OTC medicines present risks and can cause significant morbidity and mortality. To minimize these problems, the decision to self-medicate must take into account all patient's characteristics and relevant medicine information. Despite the risks, self-medication is an increasing practice worldwide and OTC medicines are easily available in stores and for online sale, without counselling from a healthcare provider, in EU and USA. In this global context, we created MEDimprove, a web platform for patients that supports responsible self-care and self-medication. The software is a clinical decision support system based on a complex algorithm that integrates all relevant patient and medicine variables and suggests the adequate safe treatment for each patient. It provides health information and personalized health counselling in a convenient, user-friendly and confidential environment. By integrating with online medicine stores, MEDimprove also gives the possibility to buy OTC medicines and other health products. For these stores, MEDimprove will increase sales by providing users with a professional and personalized counselling.Patients have free access to MEDimprove. Revenues come from: sales fees from pharmacies/medicine stores and advertising from pharmaceutical companies. We expect revenues of nearly 1.9 million euros in 3 years in a growing market of online OTC and dermocosmetics sales (which represent 15% of all online shopping and annual CAGR of the EU Market above 8%). We founded serFarma in 2014, providing innovative pharmaceutical services aiming to increase patients’ quality of life by using technology to promote the adequate use of medicines. We have invested over 150.000€ of own funds, and have started having revenues in March 2016. Dziedzina nauki natural sciencescomputer and information sciencesinternetinternet accesssocial sciencessociologydemographymortalitymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugssocial scienceseconomics and businessbusiness and managementcommercee-commercesocial scienceseconomics and businessbusiness and managementbusiness models Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Temat(-y) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator SERFARMA LDA Wkład UE netto € 50 000,00 Adres RUA INSTITUTO PEDRO NUNES ED C RUA PEDRO NUNES 3030 199 COIMBRA Portugalia Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Continente Centro (PT) Região de Coimbra Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
